Concepedia

Yu Du

YD

12

Publications

2.5K

Citations

11

H-Index

2016

Active since

Affiliations

Eli Lilly (United States)(Current)

Velocity Clinical Research (United States)

Harvard University

Yale University

Yu Du is an author at Eli Lilly (United States) specializing in medicine, pharmacology, and pharmacotherapy.

ORCID

Top concepts

Publications per year

2016–2024

12

Publications

12

Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial

Ania M. Jastreboff, Lee M. Kaplan, Juan P. Frías et al. · New England Journal of Medicine · 2023 · 830 citations

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA

Julio Rosenstock, Juan P. Frías, Ania M. Jastreboff et al. · The Lancet · 2023 · 327 citations

, , +6

LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept

Tamer Coşkun, Shweta Urva, William C. Roell et al. · Cell Metabolism · 2022 · 246 citations · Full text

Development of a Claims-based Frailty Indicator Anchored to a Well-established Frailty Phenotype

Jodi B Segal, Hsien‐Yen Chang, Yu Du et al. · Medical Care · 2017 · 229 citations · Full text

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial

Arun J. Sanyal, Lee M. Kaplan, Juan P. Frías et al. · Nature Medicine · 2024 · 186 citations · Full text

Rows per page

1–5 of 12